Medical Bulletin 06/ April/ 2024

Here are the top medical news for the day:

Study finds prebiotics and probiotics effect on depression and obesity

A recent study published in the journal Nutrients discovered the interactions between depression and nutrition, coupled with exercise.
Obesity and depression frequently co-occur, along with anxiety disorders, sharing a bidirectional relationship. Depression often leads to comfort eating and inactivity, increasing the risk of obesity by 40% during emotional stress. Conversely, obesity can heighten the likelihood of anxiety or depression due to negative self-image and societal stigma. While antidepressants effectively treat depression, they may contribute to weight gain.
In this study, researchers explored the potential of gut microbes in treating both obesity and depression, focusing on the role of probiotics and prebiotics. They found that dietary patterns influence around 57% of gut microbiota composition. Probiotics enhance the gut barrier and immune system, improving depressive symptoms. Additionally, supplementation with fatty acids and vitamins E and D, along with specific diets like the Mediterranean or DASH diets, may help counter severe depression and reduce neuroinflammation.
The findings suggested that depression and obesity risk could be reduced with both the DASH and the MD. High-quality vegetarian diets were protective against depression, underlining the pivotal role of diet quality. Furthermore, some clinical trials in humans suggested a positive effect of probiotics on depressive disorders as well as on obesity and related metabolic conditions like insulin resistance, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD).
Reference: Klaudia Sochacka,Agata Kotowska and Sabina Lachowicz-Wiśniewska; The Role of Gut Microbiota, Nutrition, and Physical Activity in Depression and Obesity—Interdependent Mechanisms/Co-Occurrence; Journal: Nutrients; https://doi.org/10.3390/nu16071039
Do newly diagnosed type 2 diabetics succeed in weight management?
A register-based study from Finland identified three distinct BMI trajectory groups among patients with newly diagnosed type 2 diabetes.
The study was carried out by researchers at the University of Eastern Finland, and was published in the journal Clinical Epidemiology.
Most type 2 diabetes (T2D) patients live with obesity, and weight loss is one of the therapeutic objectives in T2D management. Clinical trials have demonstrated that modest weight loss, i.e, 5‒10%, in T2D patients with high BMI improves the risk factors of diabetes complications, such as hyperglycaemia, hyperlipidaemia, and hypertension. Complications of type 2 diabetes (T2D) can be classified into microvascular (retinopathy, neuropathy, nephropathy) and macrovascular (cardiovascular disease, cerebrovascular disease, peripheral vascular disease) categories. Observational studies exploring the association between BMI and these complications have yielded mixed results, with some showing positive, inverse, or no associations.
In this cohort study, electronic health records from public primary and specialized healthcare services were utilized and included a total of 889 adults with newly diagnosed T2D between 2011 or 2012 (mean age at baseline 62.0 years). Individual BMI trajectories from the T2D diagnosis until 2014 were estimated. Data was collected on patients’ birth year, sex, measurements of BMI, fasting plasma glucose (FPG), glycated haemoglobin (HbA1c) and low-density lipoprotein (LDL), diagnosis codes and dates for T2D and complications, as well as the date of death.
The results revealed that in a four-year follow-up, most patients followed a stable trajectory without much weight change. Only 10% of patients lost weight, whereas 3% gained weight. Mean BMI exceeded the threshold of obesity in all groups at baseline. Patients belonging to each trajectory group were followed up for another eight years for diabetes complications. During the follow-up, 13% of all patients developed microvascular complications, 21% developed macrovascular complications and 20% of patients deceased. The risk of microvascular complications was 2.9 times higher and the risk of macrovascular complications 2.5 times higher among patients with an increasing BMI compared to those with a stable BMI.
“These results underscore the significance of continuous BMI monitoring and weight management in patients with type 2 diabetes. Tailored treatments and support with lifestyle changes are crucial for efficiently preventing weight gain and reducing the risk of diabetes complications,” said Doctoral Researcher Zhiting Wang of the University of Eastern Finland.
Reference: Zhiting Wang, Piia Lavikainen, Katja Wikström, Tiina Laatikainen; Trajectories of Body Mass Index and Risk for Diabetes Complications and All-Cause Mortality in Finnish Type 2 Diabetes Patients; Journal: Clinical Epidemiology; https://doi.org/10.2147/CLEP.S450455
Do soy products lower the risk of cancer?
In a recent review published in the journal Nutrients, researchers discussed the possible associations between the consumption of soy products and the risk of developing cancer.
Soy products are rich in compounds like isoflavones, phytosterols, and dietary fibre, all of which may mitigate cancer risk. However, research has suggested these effects vary with soy products and cancer types. Cancer rates continue to rise globally, with breast, lung, colorectal, prostate, and stomach cancers leading in terms of both new cases and deaths. Researchers have observed variations in cancer prevalence, which may be attributed to different dietary habits, particularly soy product consumption.
The study analyzed 28 studies involving 24,090 cases and 5,53,282 participants to examine the link between soy product consumption and cancer risk. High soy intake was associated with a 31% reduced risk of cancer, particularly in case-control studies, showing a 24% reduction in women but not men. Additionally, analyzing 7 cohort and 19 case-control studies with 18,729 cases and 3,12,770 participants revealed that high tofu consumption was found to significantly reduce cancer risk by 22% in both males and females.
The results observed a notable risk reduction in gynaecological cancers, including ovarian cancers, as well as cancers affecting the gastrointestinal and upper aerodigestive tract, prostate, and lungs. The dose-response analysis indicated non-linear relationships, with increased soy consumption and tofu associated with a reduced cancer risk.
The findings revealed that higher consumption of total soy foods, tofu was associated with a reduced risk of cancer, particularly gastrointestinal and gynaecological cancers. However, evidence regarding other soy products is insufficient, thus necessitating the need for additional well-designed prospective cohort studies.
Reference: Chenting Wang, Keqing Ding, Xuanzhen Xie, Jinyue Zhou,Pengju Liu,Shuang Wang, Ting Fang,Guozhang Xu, Chunlan Tang, Hang Hong; Soy Product Consumption and the Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies; Journal: Nutrients; https://doi.org/10.3390/nu16070986

Powered by WPeMatico

Sanofi new polio vaccine gets nod in India

New Delhi: Drug giant Sanofi has received a nod for an alternative injectable vaccine, IMOVAX-Polio, to replace the widely used Inactivated Polio Vaccine (IPV) ShanIP in the India.

IMOVAX-Polio shares the same composition and formulation as ShanIPV. It has been employed in over 100 countries for more than 40 years. 

“We wish to assure all stakeholders that there will be no shortage of IPV vaccines in India on our account, towards safeguarding the nation’s status of remaining polio-free. We remain fully committed to fulfilling our public health mission in India,” a Sanofi India spokesperson told PTI.

To ensure the adequate availability of the IPV vaccines, the Company has already received approvals for IMOVAX-Polio.

“…Sanofi has had to adapt its strategy and portfolio to these (emerging) trends. Accordingly, Sanofi Healthcare India Pvt Ltd (SHIPL) announced that by the end of 2023, it will discontinue ShanIPV, which was only filled and packaged at our factory in Hyderabad, India,” the spokesperson added.

ShanIPV, a trivalent inactivated injectable vaccine was launched in 2015 in India. It was administered in two stages- at six weeks and 14 weeks of age under the government’s immunization programme.

Sanofi, along with Serum Institute of India, has been at the forefront of supplying IPV vaccines in the country.

Read also: AstraZeneca-Sanofi Beyfortus approved in Japan for prevention of RSV disease in infants

Powered by WPeMatico

Dr Reddy’s Labs, Bayer collaborate to market, distribute second brand of heart failure drug Vericiguat in India

Hyderabad: Dr
Reddy’s Laboratories Ltd. and Bayer announced that both
companies have entered into a partnership to market and distribute a second
brand of Vericiguat in India.

Under the terms of this agreement, Bayer has
granted non-exclusive rights to Dr. Reddy’s under the brand name Gantra.

Vericiguat,
a soluble guanylate cyclase (sGC) stimulator, in India, is indicated, along
with guideline-based medical therapy, in adults with symptomatic chronic heart
failure with reduced ejection fraction (less than 45%), following a recent
event of worsening heart failure which required hospitalization or outpatient
intravenous (IV) diuretics. Vericiguat works on a
pathway not currently targeted by existing heart failure treatments and can
reduce the combined risk of cardiovascular death and heart failure
hospitalization in such patient. India has between
8-10 million people with heart failure, making it one of the largest populations
with this condition. 

Shweta
Rai, Managing Director, Bayer Zydus Pharma and Country Division Head (CDH) for
Bayer’s Pharmaceuticals Business in South Asia said, “Despite therapy,
chronic heart failure patients can experience disease progression that disrupts
their lives and leads to worsening heart failure events. Vericiguat can help
slow down disease progression, reduce hospital admissions and improve their chances of survival. The introduction of
a second brand of vericiguat in India, through our partnership with Dr. Reddy’s
is a reaffirmation of our commitment to making innovative healthcare solutions
accessible to as many patients as possible. We are excited about the possibilities this
partnership with Dr. Reddy’s presents in improving health outcomes for patients
with chronic HF, following a recent event of worsening heart failure.”

M.V. Ramana, Chief
Executive Officer, Branded Markets (India and Emerging Markets), Dr Reddy’s
said, “Strengthening our chronic therapy portfolio in India continues to be
a focus area for us. Vericiguat is a first-in-class sGC stimulator indicated
for adults with symptomatic, chronic HF and ejection fraction less than 45%
following worsening heart failure. The addition of Vericiguat bolsters our
heart failure management portfolio that includes Cidmus, Daplo and beta
blockers. The partnership with Bayer is part of Dr. Reddy’s continuous efforts
to make innovative medicines available to patients in India through strategic
collaborations. We will use our strengths in marketing and distribution to
widen access to this novel treatment in metros and beyond into tier-I and
tier-II towns in India.”

Heart
failure is a major public health issue affecting more than 8-10 million people
in India. The average age of an Indian heart failure patient is a decade
younger than their Western counterparts being 55 – 60 yrs. Despite the substantially
younger age of patients with HF in India, the 5-year mortality rate is 60%. In patients with
chronic heart failure, with reduced ejection fraction (less than 45%) an event
of worsening heart failure can happen at any stage. 90% of patients who suffer
from worsening heart failure are not in the advanced stage of chronic heart
failure.
HF remains the commonest cardiac cause of hospitalization in India with
worsening heart failure events being one of the most important causes of death
in heart failure patients.

Powered by WPeMatico

Screening with a PSA test has a small impact on prostate cancer deaths but leads to overdiagnosis, finds study

The largest study to date investigating a single invitation to a PSA blood test to screen for prostate cancer has found it had a small impact on reducing deaths, but also led to overdiagnosis and missed early detection of some aggressive cancers.

Powered by WPeMatico

Urine test halves painful procedures in bladder cancer follow up, new trial shows

A simple urine test can more than halve the number of cystoscopies necessary to follow up high-risk bladder cancer patients, new research has found.

Powered by WPeMatico

Five-year interval is safe for prostate cancer screening, research shows

A simple blood test every five years is sufficient to screen low risk men for prostate cancer, new research has shown.

Powered by WPeMatico

Clinical trial: First cardiac bioimplants for treatment of myocardial infarction using umbilical cord stem cells

The results of a pioneering study support the safety of the bioimplants called PeriCord, made from stem cells of the umbilical cord and pericardium from a tissue donor, which aid in the regeneration and revascularization of the affected area. The study has monitored seven interventions of this pioneering tissue engineering surgery over three years, noting excellent biocompatibility and no rejection in patients.

Powered by WPeMatico

Study finds immunotherapy combination before surgery improves outcomes for patients with pancreatic cancer

A pilot study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that for people with borderline resectable pancreatic cancer, administrating an immunotherapy drug in combination with chemotherapy before surgery is safe and may improve long-term outcomes.

Powered by WPeMatico

Marengo Asia Hospital Gurugram doctors perform key hole surgery to treat 30-year-old man with Refractory PTSD and Dyscognitive Epilepsy

Gurugram: A 30-year-old man suffering from multiple traumatic experiences till he attained 16 years of age due to domestic abuse was successfully treated by the doctors at the Marengo Asia Hospitals Gurugram through a key hole surgery.

The comprehensive approach taken by Marengo Asia Hospitals Gurugram, led by Dr Himanshu Champaneri, highlights the importance of a multidisciplinary team in addressing such cases.

He developed symptoms of post-traumatic stress disorder from the time he turned 17 years of age. *Dr Himanshu Champaneri, Sr Consultant, Neurosurgery, Marengo Asia Hospitals Gurugram treated the patient.

The patient was diagnosed with Refractory PTSD with Dyscognitive epilepsy. Refractory PTSD with dyscognitive epilepsy refers to a complex medical condition where an individual experiences both post-traumatic stress disorder (PTSD) and dyscognitive epilepsy that does not respond well to conventional treatments.

Also Read:Doctors at Faridabad Hospital perform bloodless liver transplants in 2 young girls with wilson’s disease

The disorder manifests itself in the form of memory intrusions, inability to focus, avoiding situations and contacts that will remind him of his traumatic experiences, isolation, and difficulty in establishing and maintaining relations.

The patient’s immediate relief and improved quality of life following surgery highlight the effectiveness of the intervention. His ability to engage in daily activities and envision a future free from the burden of his conditions speaks volumes about the impact of appropriate treatment.

The patient had sought medical therapies before coming to India which helped him for a certain time, when the symptoms recurred. But this affected his daily life, education, and ability to learn/concentrate. He even attempted suicide two times and was treated with medical therapy, psychotherapy, and EMDR (eye movement desensitization and reprocessing), but his symptoms continued.

He developed dyscognitive epilepsy in which he would have sudden episodes of blankness when he would lose the ability to respond to his surroundings, questions, or any dangers. Such episodes would occur anytime when he was traveling, standing at the subway station, in class, or even alone and affected his daily life as he was unable to pursue any growth in his education/profession.

When he sought treatment at Marengo Asia Hospitals Gurugram, he was evaluated by a team of psychiatrists, functional neurosurgeons, and Neurologists. When asked to revisit his traumatic memories, the functional MRI showed active signals in the right amygdala, which is expected in cases of severe refractory post-traumatic stress disorder. The non-dominant side was confirmed as right side. The rationale for intervention was to intervene at the non-dominant amygdala, which is a center for memory and fear. In cases of refractory PTSD, the non-dominant amygdala becomes hyperactive, leading to memory intrusions and giving rise to dyscognitive seizures.

The keyhole surgery was performed using stereotactic radiofrequency ablation. This procedure is performed by identifying the hyperactive target, the right amygdala in this case. The surgery is performed while the patient is awake to ensure that we have reached the right target and that there are no neurological side effects.

During the surgery, when the amygdala was stimulated and ablated, the patient felt sudden relief of tension, he felt happy memories and relaxation of muscles which he had not experienced for many years. This confirmed the success of the surgery and ablation of the right area. A post-operative MRI scan additionally confirmed this.

According to an IANS report, After the surgery, the patient remained in a very relaxed and happy state and was able to focus on tasks that had not been possible before. He was able to read books, focus on videos, and think about his future with such clarity, which he had not experienced for many years. He did not have any episodes of dyscognitive seizures after the surgery and he had complete relief from the post-traumatic stress disorder.

Dr Himanshu Champaneri, Senior Consultant Neurosurgeon, at Marengo Asia Hospital Gurugram, said,, “When someone has both refractory PTSD and dyscognitive epilepsy, it can pose significant challenges in diagnosis and treatment. The presence of one condition can exacerbate the symptoms of the other, leading to a complex clinical picture. Managing this condition typically involves a multidisciplinary approach, including mental health professionals, neurologists, and possibly other specialists, to address both the psychiatric and neurological aspects of the disorder. Treatment may involve a combination of medication, psychotherapy, and possibly other interventions such as neuromodulation or lifestyle modifications.”

Neeta Rajwar, Facility Director, Marengo Asia Hospitals Gurugram says, “Our clinicians constantly endeavor to break the ceiling to go beyond borders to treat patients who come to us. Within the comprehensive realm of health and wellness, prioritizing mental health is equally vital to physical well-being. These facets are intertwined, each influencing the other’s welfare. While research findings may differ, data from India indicates that approximately 20% of adults grapple with various mental health challenges. Globally, mental health is swiftly becoming a growing area of concern. Unchecked mental disorders can lead to disastrous diseases such as epilepsy”, reports IANS.

WHO studies estimated that the burden of mental health problems in India is 2443 disability-adjusted life years (DALYs) per 100 000 population; the age-adjusted suicide rate per 100 000 population is 21.1. close to 60 to 70 million people in India suffer from common to severe mental disorders. A study has shown that children who have experienced child abuse or neglect are four times more likely to develop serious mental illness. And yet, there are many reasons why people do not seek treatment for mental illness, including stigma, lack of awareness still very low even among the literate, and lack of access to resources.

Powered by WPeMatico

No significant interaction between treatment strategy with intravascular imaging-guided PCI and sex: JAMA

Korea: A subgroup analysis of the RENOVATE-COMPLEX-PCI trial including 1639 patients showed no significant interaction between treatment strategy and sex in patients undergoing complex PCI with the treatment benefit of intravascular imaging–guided PCI.

“In the analysis, intravascular imaging guidance was associated with reducing the risk of target vessel failure in both women and men,” the researchers reported in JAMA Cardiology. “There was no significant interaction between treatment strategy with intravascular imaging-guided percutaneous coronary intervention (PCI) and sex.”

Previous studies revealed that women often had worse clinical outcomes after PCI than men. Potential causes for this discrepancy were suggested to be older age, atypical presentation, and a higher number of underlying risk factors in women. Recent studies also found that women tend to experience a higher incidence of adverse outcomes after PCI of complex coronary artery lesions, however, these differences were minimized after adjusting for underlying risk factors.

There have been heterogeneous results related to sex differences in prognosis after PCI for complex coronary artery lesions. Therefore, Ji Hyun Cha, Sungkyunkwan University School of Medicine, Seoul, Korea, and colleagues aimed to evaluate potential differences in outcomes with intravascular imaging–guided PCI of complex coronary artery lesions between men and women.

For this purpose, the researchers conducted a prespecified substudy to evaluate the interaction of sex in the RENOVATE-COMPLEX-PCI randomized clinical trial. The trial, conducted at 20 sites in Korea, evaluated patients with complex coronary artery lesions treated by PCI. It showed superior clinical outcomes following intravascular imaging–guided PCI versus angiography-guided PCI.

Patients with complex coronary artery lesions undergoing PCI were enrolled between 2018 and 2021, and the median follow-up period was 2.1 years.

Following diagnostic coronary angiography, eligible patients were randomly assigned in a ratio of 2:1 to receive intravascular imaging–guided PCI or angiography-guided PCI. The timing and choice of the intravascular imaging device were left to the operators’ discretion. Of 1639 included patients, 20.7% were women, and the mean age was 65.6 years.

The study’s primary endpoint was target vessel failure, defined as a composite of target vessel-related myocardial infarction, cardiac death, or clinically driven target vessel revascularization. Secondary endpoints were individual components of the primary endpoint.

Based on the analysis, the researchers reported the following findings:

  • There was no difference in the risk of the primary endpoint between women and men (9.4% vs 8.3%; adjusted hazard ratio [HR], 1.39).
  • Intravascular imaging–guided PCI tended to have a lower incidence of the primary endpoint than angiography-guided PCI in both men (8.3% versus 11.7%; adjusted HR, 0.72) and women (5.2% vs 14.5%; adjusted HR, 0.34) without significant interaction.

In conclusion, intravascular imaging versus angiographic guidance was associated with a similar reduction in the risk of target vessel failure among women and men among patients undergoing complex PCI. The treatment benefit of imaging-guided PCI showed no significant interaction between sex and treatment strategy.

Reference:

Cha JH, Lee JM, Choi KH, et al. Intravascular Imaging–Guided Optimization of Complex Percutaneous Coronary Intervention by Sex: A Subgroup Analysis of the RENOVATE-COMPLEX-PCI Trial. JAMA Cardiol. Published online April 03, 2024. doi:10.1001/jamacardio.2024.0291

Powered by WPeMatico